CytomX Therapeutics, Inc. (CTMX) Financial Statements
CytomX Therapeutics, Inc. (CTMX) reported trailing twelve-month revenue of $18.3M (down 87.0% year on year) and net income of -$79.7M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$82.5M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
CTMXCytomX Therapeutics, Inc.Follow CTMX — free
—
Price chart with a free account
- Market cap
- 505.5M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 10 Nov, in 17 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7.7 | 15.0 | 71.6 | 59.5 | 26.9 | 68.4 | 37.3 | 53.2 | 101.2 | 138.1 | 76.2 | 18.3 | |
| Research & development | 28.4 | 54.8 | 92.3 | 103.9 | 131.6 | 112.9 | 114.2 | 111.6 | 77.7 | 83.4 | 68.7 | 73.4 | |
| Operating income | -33.2 | -59.6 | -46.3 | -77.9 | -141.5 | -80.5 | -116.0 | -101.3 | -6.5 | 25.0 | -22.4 | -87.2 | |
| Pre-tax income | -35.4 | -58.9 | -43.6 | -70.3 | -133.3 | -78.7 | -115.9 | -99.3 | 3.3 | 32.1 | -17.1 | -79.4 | |
| Income tax | 0.0 | -0.0 | -0.5 | 14.3 | -0.4 | -13.9 | 0.0 | 0.0 | 3.9 | 0.2 | 0.2 | 0.2 | |
| Net income | -35.4 | -58.9 | -43.1 | -84.6 | -132.8 | -64.8 | -115.9 | -99.3 | -0.6 | 31.9 | -17.4 | -79.7 | |
| Diluted EPS ($) | -4.90 | -1.63 | -1.16 | — | — | — | -1.81 | -1.51 | -0.01 | 0.38 | -0.15 | -0.36 | |
| Diluted shares (mn) | — | — | — | — | — | — | 64.1 | 65.7 | 73.8 | 84.7 | 137.9 | — |
USD millions · SEC XBRL
CytomX Therapeutics, Inc. — questions
- What is CytomX Therapeutics, Inc.'s revenue?
- $18.3M over the twelve months to 2026-06-30, down 87.0% year on year, from its 10-Q and 10-K filings.
- What is CytomX Therapeutics, Inc.'s net income?
- -$79.7M over the twelve months to 2026-06-30.
- What is CytomX Therapeutics, Inc.'s free cash flow?
- -$82.5M over the twelve months to 2026-06-30.
- What are CytomX Therapeutics, Inc.'s diluted earnings per share?
- $-0.36 over the twelve months to 2026-06-30.
Every figure on this page comes from CytomX Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.